{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:25:52Z","timestamp":1791314752820,"version":"4.3.1"},"reference-count":67,"publisher":"Walter de Gruyter GmbH","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,1,31]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Obstructive Sleep Apnea (OSA) is a prevalent sleep disorder marked by repeated episodes of partial or complete upper airway obstruction during sleep, which leads to intermittent hypoxia and fragmented sleep. These disruptions negatively impact cardiovascular health, metabolic function, and overall quality of life. Obesity is a\u00a0major modifiable risk factor for OSA, as it contributes to\u00a0both anatomical and physiological mechanisms that increase the likelihood of airway collapse during sleep. While continuous positive airway pressure (CPAP) therapy remains the gold standard for OSA treatment, its limitations\u00a0\u2013 particularly issues with patient adherence\u00a0\u2013 underscore the need for alternative or\u00a0adjunct therapeutic options. One such option is the use of\u00a0glucagon-like peptide-1 receptor agonists (GLP-1 RAs), which are widely recognized for their ability to reduce body weight and improve metabolic health. Emerging evidence suggests that GLP-1 RAs may offer therapeutic benefits in managing OSA, particularly by addressing obesity, a key contributor to the condition. This narrative review seeks to explore the role of GLP-1 RAs in the treatment of OSA, evaluating their efficacy in reducing OSA severity and discussing their broader clinical implications for future research and practice.<\/jats:p>","DOI":"10.1515\/jbcpp-2024-0193","type":"journal-article","created":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T12:10:27Z","timestamp":1736770227000},"page":"13-25","source":"Crossref","is-referenced-by-count":9,"title":["Exploring the therapeutic potential of GLP-1 receptor agonists in the management of obstructive sleep apnea: a comprehensive review"],"prefix":"10.1515","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-1618-0606","authenticated-orcid":false,"given":"Amruth Akhil","family":"Alluri","sequence":"first","affiliation":[{"name":"Internal Medicine, American University of the Caribbean School of Medicine , Cupecoy , Sint Maarten"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merin","family":"Mohan Kurien","sequence":"additional","affiliation":[{"name":"Acute Medicine , Calderdale and Huddersfield NHS Foundation Trust , Huddersfield , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikhil Patel","family":"Pokar","sequence":"additional","affiliation":[{"name":"Internal Medicine , Malla Reddy Institute of Medical Sciences , Hyderabad , Telangana , India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alekhya","family":"Madarapu","sequence":"additional","affiliation":[{"name":"Internal Medicine , Government Medical College Nizamabad , Nizamabad , Telangana , India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sreeja","family":"Sadam","sequence":"additional","affiliation":[{"name":"Internal Medicine , Government Medical College Mahabubnagar , Mahabubnagar , Telangana , India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikhitha","family":"Puvvala","sequence":"additional","affiliation":[{"name":"Internal Medicine , Malla Reddy Institute of Medical Sciences , Hyderabad , Telangana , India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4605-2805","authenticated-orcid":false,"given":"Rajmohan","family":"Seetharaman","sequence":"additional","affiliation":[{"name":"Pharmacology, MGM Medical College and Hospital, MGM Institute of Health Sciences , Nerul, Navi Mumbai , Maharashtra , India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2025,1,14]]},"reference":[{"key":"2025121209195693612_j_jbcpp-2024-0193_ref_001","doi-asserted-by":"crossref","unstructured":"Jordan, AS, McSharry, DG, Malhotra, A. Adult obstructive sleep apnoea. Lancet 2014;383:736\u201347. https:\/\/doi.org\/10.1016\/S0140-6736(13)60734-5.","DOI":"10.1016\/S0140-6736(13)60734-5"},{"key":"2025121209195693612_j_jbcpp-2024-0193_ref_002","doi-asserted-by":"crossref","unstructured":"Tai, JE, Phillips, CL, Yee, BJ, Grunstein, RR. Obstructive sleep apnoea in obesity: a review. Clin Obes 2024;14. https:\/\/doi.org\/10.1111\/cob.12651.","DOI":"10.1111\/cob.12651"},{"key":"2025121209195693612_j_jbcpp-2024-0193_ref_003","doi-asserted-by":"crossref","unstructured":"Santilli, M, Manciocchi, E, D\u2019Addazio, G, Di Maria, E, D\u2019Attilio, M, Femminella, B, et al.. Prevalence of obstructive sleep apnea syndrome: a single-center retrospective study. Int J Environ Res Public Health 2021;18:10277. https:\/\/doi.org\/10.3390\/ijerph181910277.","DOI":"10.3390\/ijerph181910277"},{"key":"2025121209195693612_j_jbcpp-2024-0193_ref_004","doi-asserted-by":"crossref","unstructured":"Senaratna, CV, Perret, JL, Lodge, CJ, Lowe, AJ, Campbell, BE, Matheson, MC, et al.. Prevalence of obstructive sleep apnea in the general population: a systematic review. Sleep Med Rev 2017;34:70\u201381. https:\/\/doi.org\/10.1016\/j.smrv.2016.07.002.","DOI":"10.1016\/j.smrv.2016.07.002"},{"key":"2025121209195693612_j_jbcpp-2024-0193_ref_005","doi-asserted-by":"crossref","unstructured":"Kapur, V, Strohl, KP, Redline, S, Iber, C, O\u2019Connor, G, Nieto, J. Underdiagnosis of sleep apnea syndrome in U.S. Communities. Sleep Breath 2002;06:049\u201354. https:\/\/doi.org\/10.1055\/s-2002-32318.","DOI":"10.1055\/s-2002-32318"},{"key":"2025121209195693612_j_jbcpp-2024-0193_ref_006","doi-asserted-by":"crossref","unstructured":"Ge, X, Han, F, Huang, Y, Zhang, Y, Yang, T, Bai, C, et al.. Is obstructive sleep apnea associated with cardiovascular and all-cause mortality? PLoS One 2013;8:e69432. https:\/\/doi.org\/10.1371\/journal.pone.0069432.","DOI":"10.1371\/journal.pone.0069432"},{"key":"2025121209195693612_j_jbcpp-2024-0193_ref_007","doi-asserted-by":"crossref","unstructured":"Salman, LA, Shulman, R, Cohen, JB. Obstructive sleep apnea, hypertension, and cardiovascular risk: epidemiology, pathophysiology, and management. Curr Cardiol Rep 2020;22:6. https:\/\/doi.org\/10.1007\/s11886-020-1257-y.","DOI":"10.1007\/s11886-020-1257-y"},{"key":"2025121209195693612_j_jbcpp-2024-0193_ref_008","doi-asserted-by":"crossref","unstructured":"Patel, JA, Ray, BJ, Fernandez-Salvador, C, Gouveia, C, Zaghi, S, Camacho, M. Neuromuscular function of the soft palate and uvula in snoring and obstructive sleep apnea: a systematic review. Am J Otolaryngol 2018;39:327\u201337. https:\/\/doi.org\/10.1016\/j.amjoto.2018.03.006.","DOI":"10.1016\/j.amjoto.2018.03.006"},{"key":"2025121209195693612_j_jbcpp-2024-0193_ref_009","doi-asserted-by":"crossref","unstructured":"Liu, X, Ma, Y, Ouyang, R, Zeng, Z, Zhan, Z, Lu, H, et al.. The relationship between inflammation and neurocognitive dysfunction in obstructive sleep apnea syndrome. J Neuroinflammat 2020;17:229. https:\/\/doi.org\/10.1186\/s12974-020-01905-2.","DOI":"10.1186\/s12974-020-01905-2"},{"key":"2025121209195693612_j_jbcpp-2024-0193_ref_010","doi-asserted-by":"crossref","unstructured":"Schwartz, AR, Patil, SP, Laffan, AM, Polotsky, V, Schneider, H, Smith, PL. Obesity and obstructive sleep apnea: pathogenic mechanisms and therapeutic approaches. Proc Am Thorac Soc 2008;5:185\u201392. https:\/\/doi.org\/10.1513\/pats.200708-137MG.","DOI":"10.1513\/pats.200708-137MG"},{"key":"2025121209195693612_j_jbcpp-2024-0193_ref_011","doi-asserted-by":"crossref","unstructured":"Alterki, A, Abu-Farha, M, Al Shawaf, E, Al-Mulla, F, Abubaker, J. Investigating the relationship between obstructive sleep apnoea, inflammation and cardio-metabolic diseases. Int J Mol Sci 2023;24:6807. https:\/\/doi.org\/10.3390\/ijms24076807.","DOI":"10.3390\/ijms24076807"},{"key":"2025121209195693612_j_jbcpp-2024-0193_ref_012","doi-asserted-by":"crossref","unstructured":"Platon, AL, Stelea, CG, Boi\u0219teanu, O, Patrascanu, E, Zetu, IN, Ro\u0219u, SN, et al.. An update on obstructive sleep apnea syndrome\u2013a literature review. Med (B Aires) 2023;59:1459. https:\/\/doi.org\/10.3390\/medicina59081459.","DOI":"10.3390\/medicina59081459"},{"key":"2025121209195693612_j_jbcpp-2024-0193_ref_013","doi-asserted-by":"crossref","unstructured":"Chang, H, Chen, Y, Du, J. Obstructive sleep apnea treatment in adults. Kaohsiung J Med Sci 2020;36:7\u201312. https:\/\/doi.org\/10.1002\/kjm2.12130.","DOI":"10.1002\/kjm2.12130"},{"key":"2025121209195693612_j_jbcpp-2024-0193_ref_014","doi-asserted-by":"crossref","unstructured":"Sara\u00e7, S, Af\u015far, G\u00c7, Oru\u00e7, \u00d6, Top\u00e7uo\u011flu, \u00d6B, Salt\u00fcrk, C, Peker, Y. Impact of patient education on compliance with positive airway pressure treatment in obstructive sleep apnea. Med Sci Mon 2017;23:1792\u20139. https:\/\/doi.org\/10.12659\/MSM.902075.","DOI":"10.12659\/MSM.902075"},{"key":"2025121209195693612_j_jbcpp-2024-0193_ref_015","doi-asserted-by":"crossref","unstructured":"Rosvall, BR, Chin, CJ. Is uvulopalatopharyngoplasty effective in obstructive sleep apnea? Laryngoscope 2017;127:2201\u20132. https:\/\/doi.org\/10.1002\/lary.26631.","DOI":"10.1002\/lary.26631"},{"key":"2025121209195693612_j_jbcpp-2024-0193_ref_016","doi-asserted-by":"crossref","unstructured":"Mashaqi, S, Patel, SI, Combs, D, Estep, L, Helmick, S, Machamer, J, et al.. The hypoglossal nerve stimulation as a novel therapy for treating obstructive sleep apnea\u2013a literature review. Int J Environ Res Public Health 2021;18:1642. https:\/\/doi.org\/10.3390\/ijerph18041642.","DOI":"10.3390\/ijerph18041642"},{"key":"2025121209195693612_j_jbcpp-2024-0193_ref_017","doi-asserted-by":"crossref","unstructured":"Carneiro-Barrera, A, Amaro-Gahete, FJ, Guill\u00e9n-Riquelme, A, Jurado-Fasoli, L, S\u00e1ez-Roca, G, Mart\u00edn-Carrasco, C, et al.. Effect of an interdisciplinary weight loss and lifestyle intervention on obstructive sleep apnea severity. JAMA Netw Open 2022;5:e228212. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.8212.","DOI":"10.1001\/jamanetworkopen.2022.8212"},{"key":"2025121209195693612_j_jbcpp-2024-0193_ref_018","doi-asserted-by":"crossref","unstructured":"Ruda, AI, Ciobanu, DM, Inceu, G, Rusu, A, Roman, G. The effect of Dulaglutide on glycemic and weight control in patients with type 2 diabetes. Med Pharm Rep 2023;96:52. https:\/\/doi.org\/10.15386\/MPR-2425.","DOI":"10.15386\/mpr-2425"},{"key":"2025121209195693612_j_jbcpp-2024-0193_ref_019","doi-asserted-by":"crossref","unstructured":"Bonora, E, Frias, JP, Tinahones, FJ, Van, J, Malik, RE, Yu, Z, et al.. Effect of dulaglutide 3.0 and 4.5\u00a0mg on weight in patients with type 2 diabetes: exploratory analyses of AWARD-11. Diabetes Obes Metab 2021;23:2242\u201350. https:\/\/doi.org\/10.1111\/DOM.14465.","DOI":"10.1111\/dom.14465"},{"key":"2025121209195693612_j_jbcpp-2024-0193_ref_020","doi-asserted-by":"crossref","unstructured":"Blackman, A, Foster, GD, Zammit, G, Rosenberg, R, Aronne, L, Wadden, T, et al.. Effect of liraglutide 3.0\u00a0mg in individuals with obesity and moderate or severe obstructive sleep apnea: the scale sleep apnea randomized clinical trial. Int J Obes 2016;40:1310\u20139. https:\/\/doi.org\/10.1038\/ijo.2016.52.","DOI":"10.1038\/ijo.2016.52"},{"key":"2025121209195693612_j_jbcpp-2024-0193_ref_021","doi-asserted-by":"crossref","unstructured":"Wilding, JPH, Batterham, RL, Davies, M, Van Gaal, LF, Kandler, K, Konakli, K, et al.. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab 2022;24:1553\u201364. https:\/\/doi.org\/10.1111\/dom.14725.","DOI":"10.1111\/dom.14725"},{"key":"2025121209195693612_j_jbcpp-2024-0193_ref_022","doi-asserted-by":"crossref","unstructured":"Pi-Sunyer, X, Astrup, A, Fujioka, K, Greenway, F, Halpern, A, Krempf, M, et al.. A randomized, controlled trial of 3.0\u00a0mg of liraglutide in weight management. N Engl J Med 2015;373:11\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1411892.","DOI":"10.1056\/NEJMoa1411892"},{"key":"2025121209195693612_j_jbcpp-2024-0193_ref_023","doi-asserted-by":"crossref","unstructured":"Gao, X, Hua, X, Wang, X, Xu, W, Zhang, Y, Shi, C, et al.. Efficacy and safety of semaglutide on weight loss in obese or overweight patients without diabetes: a systematic review and meta-analysis of randomized controlled trials. Front Pharmacol 2022;13. https:\/\/doi.org\/10.3389\/FPHAR.2022.935823.","DOI":"10.3389\/fphar.2022.935823"},{"key":"2025121209195693612_j_jbcpp-2024-0193_ref_024","doi-asserted-by":"crossref","unstructured":"Gerstein, HC, Colhoun, HM, Dagenais, GR, Diaz, R, Lakshmanan, M, Pais, P, et al.. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 2019;394:121\u201330. https:\/\/doi.org\/10.1016\/S0140-6736(19)31149-3.","DOI":"10.1016\/S0140-6736(19)31149-3"},{"key":"2025121209195693612_j_jbcpp-2024-0193_ref_026","doi-asserted-by":"crossref","unstructured":"Papaetis, GS. GLP-1 receptor agonists, SGLT-2 inhibitors, and obstructive sleep apnoea: can new allies face an old enemy? Arch Med Sci Atheroscl Dis 2023;8:e19\u201334. https:\/\/doi.org\/10.5114\/amsad\/161170.","DOI":"10.5114\/amsad\/161170"},{"key":"2025121209195693612_j_jbcpp-2024-0193_ref_029","doi-asserted-by":"crossref","unstructured":"Nauck, MA, Quast, DR, Wefers, J, Meier, JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes\u00a0\u2013 state-of-the-art. Mol Metab 2021;46. https:\/\/doi.org\/10.1016\/j.molmet.2020.101102.","DOI":"10.1016\/j.molmet.2020.101102"},{"key":"2025121209195693612_j_jbcpp-2024-0193_ref_030","doi-asserted-by":"crossref","unstructured":"Ma, X, Bruning, J, Ashcroft, FM. Glucagon-like peptide 1 stimulates hypothalamic proopiomelanocortin neurons. J Neurosci 2007;27:7125\u20139. https:\/\/doi.org\/10.1523\/JNEUROSCI.1025-07.2007.","DOI":"10.1523\/JNEUROSCI.1025-07.2007"},{"key":"2025121209195693612_j_jbcpp-2024-0193_ref_035","doi-asserted-by":"crossref","unstructured":"Dragonieri, S, Portacci, A, Quaranta, VN, Carratu, P, Lazar, Z, Carpagnano, GE, et al.. Therapeutic potential of glucagon-like peptide-1 receptor agonists in obstructive sleep apnea syndrome management: a narrative review. Diseases 2024;12:224. https:\/\/doi.org\/10.3390\/diseases12090224.","DOI":"10.3390\/diseases12090224"},{"key":"2025121209195693612_j_jbcpp-2024-0193_ref_036","doi-asserted-by":"crossref","unstructured":"Le, KDR, Le, K, Foo, F. The impact of glucagon-like peptide 1 receptor agonists on obstructive sleep apnoea: a scoping review. Pharmacy 2024;12:11. https:\/\/doi.org\/10.3390\/pharmacy12010011.","DOI":"10.3390\/pharmacy12010011"},{"key":"2025121209195693612_j_jbcpp-2024-0193_ref_038","doi-asserted-by":"crossref","unstructured":"Bell, GI, Santerre, RF, Mullenbach, GT. Hamster preproglucagon contains the sequence of glucagon and two related peptides. Nature 1983;302:716\u20138. https:\/\/doi.org\/10.1038\/302716a0.","DOI":"10.1038\/302716a0"},{"key":"2025121209195693612_j_jbcpp-2024-0193_ref_039","doi-asserted-by":"crossref","unstructured":"Turton, MD, O\u2019Shea, D, Gunn, I, Beak, SA, Edwards, CMB, Meeran, K, et al.. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 1996;379:69\u201372. https:\/\/doi.org\/10.1038\/379069a0.","DOI":"10.1038\/379069a0"},{"key":"2025121209195693612_j_jbcpp-2024-0193_ref_040","doi-asserted-by":"crossref","unstructured":"Ichimura, A, Hirasawa, A, Poulain-Godefroy, O, Bonnefond, A, Hara, T, Yengo, L, et al.. Dysfunction of lipid sensor GPR120 leads to obesity in both mouse and human. Nature 2012;483:350\u20134. https:\/\/doi.org\/10.1038\/nature10798.","DOI":"10.1038\/nature10798"},{"key":"2025121209195693612_j_jbcpp-2024-0193_ref_041","doi-asserted-by":"crossref","unstructured":"Matsumoto, T, Harada, N, Azuma, M, Chihara, Y, Murase, K, Tachikawa, R, et al.. Plasma incretin levels and dipeptidyl peptidase-4 activity in patients with obstructive sleep apnea. Ann Am Thorac Soc 2016;13:1378\u201387. https:\/\/doi.org\/10.1513\/AnnalsATS.201510-697OC.","DOI":"10.1513\/AnnalsATS.201510-697OC"},{"key":"2025121209195693612_j_jbcpp-2024-0193_ref_042","doi-asserted-by":"crossref","unstructured":"Meszaros, M, Bikov, A. Obstructive sleep apnoea and lipid metabolism: the summary of evidence and future perspectives in the pathophysiology of OSA-associated dyslipidaemia. Biomedicines 2022;10:2754. https:\/\/doi.org\/10.3390\/biomedicines10112754.","DOI":"10.3390\/biomedicines10112754"},{"key":"2025121209195693612_j_jbcpp-2024-0193_ref_043","doi-asserted-by":"crossref","unstructured":"Hoffman, S, Adeli, K. Glucagon-like peptide (GLP)-1 regulation of lipid and lipoprotein metabolism. Med Rev 2024;4:301\u201311. https:\/\/doi.org\/10.1515\/mr-2024-0011.","DOI":"10.1515\/mr-2024-0011"},{"key":"2025121209195693612_j_jbcpp-2024-0193_ref_044","doi-asserted-by":"crossref","unstructured":"Farr, S, Taher, J, Adeli, K. Glucagon-like peptide-1 as a key regulator of lipid and lipoprotein metabolism in fasting and postprandial states. Cardiovasc Haematol Disord\u00a0\u2013 Drug Targets 2014;14:126\u201336. https:\/\/doi.org\/10.2174\/1871529X14666140505125300.","DOI":"10.2174\/1871529X14666140505125300"},{"key":"2025121209195693612_j_jbcpp-2024-0193_ref_045","doi-asserted-by":"crossref","unstructured":"Farr, S, Taher, J, Adeli, K. Central nervous system regulation of intestinal lipid and lipoprotein metabolism. Curr Opin Lipidol 2016;27:1\u20137. https:\/\/doi.org\/10.1097\/MOL.0000000000000254.","DOI":"10.1097\/MOL.0000000000000254"},{"key":"2025121209195693612_j_jbcpp-2024-0193_ref_046","doi-asserted-by":"crossref","unstructured":"Grau-Bov\u00e9, C, Gonz\u00e1lez-Quilen, C, Cantini, G, Nardini, P, Espina, B, Bani, D, et al.. GLP1 exerts paracrine activity in the intestinal lumen of human colon. Int J Mol Sci 2022;23:3523. https:\/\/doi.org\/10.3390\/ijms23073523.","DOI":"10.3390\/ijms23073523"},{"key":"2025121209195693612_j_jbcpp-2024-0193_ref_047","doi-asserted-by":"crossref","unstructured":"Bikov, A, Meszaros, M, Schwarz, EI. Coagulation and fibrinolysis in obstructive sleep apnoea. Int J Mol Sci 2021;22:2834. https:\/\/doi.org\/10.3390\/ijms22062834.","DOI":"10.3390\/ijms22062834"},{"key":"2025121209195693612_j_jbcpp-2024-0193_ref_048","doi-asserted-by":"crossref","unstructured":"Zakrzewski, M, Zakrzewska, E, Kici\u0144ski, P, Przybylska-Ku\u0107, S, Dyba\u0142a, A, My\u015bli\u0144ski, W, et al.. Evaluation of fibrinolytic inhibitors: alpha-2-antiplasmin and plasminogen activator inhibitor 1 in patients with obstructive sleep apnoea. PLoS One 2016;11:e0166725. https:\/\/doi.org\/10.1371\/journal.pone.0166725.","DOI":"10.1371\/journal.pone.0166725"},{"key":"2025121209195693612_j_jbcpp-2024-0193_ref_049","doi-asserted-by":"crossref","unstructured":"Rangemark, C, Hedner, JA, Carlson, JT, Gleerup, G, Winther, K. Platelet function and fibrinolytic activity in hypertensive and normotensive sleep apnea patients. Sleep 1995;18:188\u201394. https:\/\/doi.org\/10.1093\/sleep\/18.3.188.","DOI":"10.1093\/sleep\/18.3.188"},{"key":"2025121209195693612_j_jbcpp-2024-0193_ref_050","doi-asserted-by":"crossref","unstructured":"Bagai, K, Muldowney, JAS, Song, Y, Wang, L, Bagai, J, Artibee, KJ, et al.. Circadian variability of fibrinolytic markers and endothelial function in patients with obstructive sleep apnea. Sleep 2014;37:359\u201367. https:\/\/doi.org\/10.5665\/sleep.3414.","DOI":"10.5665\/sleep.3414"},{"key":"2025121209195693612_j_jbcpp-2024-0193_ref_051","doi-asserted-by":"crossref","unstructured":"Steven, S, Jurk, K, Kopp, M, Kr\u00f6ller-Sch\u00f6n, S, Mikhed, Y, Schwierczek, K, et al.. Glucagon\u2010like peptide\u20101 receptor signalling reduces microvascular thrombosis, nitro\u2010oxidative stress and platelet activation in endotoxaemic mice. Br J Pharmacol 2017;174:1620\u201332. https:\/\/doi.org\/10.1111\/bph.13549.","DOI":"10.1111\/bph.13549"},{"key":"2025121209195693612_j_jbcpp-2024-0193_ref_052","doi-asserted-by":"crossref","unstructured":"Bikov, A, Kunos, L, P\u00e1llinger, \u00c9, L\u00e1z\u00e1r, Z, Kis, A, Horv\u00e1th, G, et al.. Diurnal variation of circulating microvesicles is associated with the severity of obstructive sleep apnoea. Sleep Breath 2017;21:595\u2013600. https:\/\/doi.org\/10.1007\/s11325-017-1464-y.","DOI":"10.1007\/s11325-017-1464-y"},{"key":"2025121209195693612_j_jbcpp-2024-0193_ref_053","doi-asserted-by":"crossref","unstructured":"Horv\u00e1th, P, L\u00e1z\u00e1r, Z, G\u00e1lffy, G, Pusk\u00e1s, R, Kunos, L, Gy, L, et al.. Circulating P-selectin glycoprotein ligand 1 and P-selectin levels in obstructive sleep apnea patients. Lung 2020;198:173\u20139. https:\/\/doi.org\/10.1007\/s00408-019-00299-0.","DOI":"10.1007\/s00408-019-00299-0"},{"key":"2025121209195693612_j_jbcpp-2024-0193_ref_054","doi-asserted-by":"crossref","unstructured":"Burger, PC, Wagner, DD. Platelet P-selectin facilitates atherosclerotic lesion development. Blood 2003;101:2661\u20136. https:\/\/doi.org\/10.1182\/blood-2002-07-2209.","DOI":"10.1182\/blood-2002-07-2209"},{"key":"2025121209195693612_j_jbcpp-2024-0193_ref_055","doi-asserted-by":"crossref","unstructured":"P\u00e1k\u00f3, J, Kunos, L, M\u00e9sz\u00e1ros, M, T\u00e1rnoki, DL, T\u00e1rnoki, \u00c1D, Horv\u00e1th, I, et al.. Decreased levels of anti-aging Klotho in obstructive sleep apnea. Rejuvenation Res 2020;23:256\u201361. https:\/\/doi.org\/10.1089\/rej.2019.2183.","DOI":"10.1089\/rej.2019.2183"},{"key":"2025121209195693612_j_jbcpp-2024-0193_ref_056","doi-asserted-by":"crossref","unstructured":"Cao, F, Wu, K, Zhu, Y-Z, Bao, Z-W. Roles and mechanisms of dipeptidyl peptidase 4 inhibitors in vascular aging. Front Endocrinol 2021;12. https:\/\/doi.org\/10.3389\/fendo.2021.731273.","DOI":"10.3389\/fendo.2021.731273"},{"key":"2025121209195693612_j_jbcpp-2024-0193_ref_057","doi-asserted-by":"crossref","unstructured":"Prud\u2019homme, GJ, Wang, Q. Anti-inflammatory role of the Klotho protein and relevance to aging. Cells 2024;13:1413. https:\/\/doi.org\/10.3390\/cells13171413.","DOI":"10.3390\/cells13171413"},{"key":"2025121209195693612_j_jbcpp-2024-0193_ref_058","doi-asserted-by":"crossref","unstructured":"Kis, A, Meszaros, M, Tarnoki, DL, Tarnoki, AD, Lazar, Z, Horvath, P, et al.. Exhaled carbon monoxide levels in obstructive sleep apnoea. J Breath Res 2019;13:036012. https:\/\/doi.org\/10.1088\/1752-7163\/ab231d.","DOI":"10.1088\/1752-7163\/ab231d"},{"key":"2025121209195693612_j_jbcpp-2024-0193_ref_059","doi-asserted-by":"crossref","unstructured":"Horvath, I, Donnelly, LE, Kiss, A, Paredi, P, Kharitonov, SA, Barnes, PJ. Raised levels of exhaled carbon monoxide are associated with an increased expression of heme oxygenase-1 in airway macrophages in asthma: a new marker of oxidative stress. Thorax 1998;53:668\u201372. https:\/\/doi.org\/10.1136\/thx.53.8.668.","DOI":"10.1136\/thx.53.8.668"},{"key":"2025121209195693612_j_jbcpp-2024-0193_ref_060","doi-asserted-by":"crossref","unstructured":"Yin, F, Liu, J, Zheng, X, Guo, L. GLP-1 receptor plays a critical role in geniposide-induced expression of heme oxygenase-1 in PC12 cells. Acta Pharmacol Sin 2010;31:540\u20135. https:\/\/doi.org\/10.1038\/aps.2010.28.","DOI":"10.1038\/aps.2010.28"},{"key":"2025121209195693612_j_jbcpp-2024-0193_ref_061","unstructured":"The relationship of hypertension with obesity and obstructive sleep apnea in adolescents\u00a0\u2013 PubMed n.d. https:\/\/pubmed.ncbi.nlm.nih.gov\/32068974\/ [Accessed 6 Oct 2024]."},{"key":"2025121209195693612_j_jbcpp-2024-0193_ref_062","doi-asserted-by":"crossref","unstructured":"Wadden, TA, Bailey, TS, Billings, LK, Davies, M, Frias, JP, Koroleva, A, et al.. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial. JAMA 2021;325:1403\u201313. https:\/\/doi.org\/10.1001\/jama.2021.1831.","DOI":"10.1001\/jama.2021.1831"},{"key":"2025121209195693612_j_jbcpp-2024-0193_ref_063","doi-asserted-by":"crossref","unstructured":"Jiang, W, Li, W, Cheng, J, Li, W, Cheng, F. Efficacy and safety of liraglutide in patients with type 2 diabetes mellitus and severe obstructive sleep apnea. Sleep Breath 2023;27:1687\u201394. https:\/\/doi.org\/10.1007\/s11325-022-02768-y.","DOI":"10.1007\/s11325-022-02768-y"},{"key":"2025121209195693612_j_jbcpp-2024-0193_ref_066","doi-asserted-by":"crossref","unstructured":"Ji, L, Gao, L, Jiang, H, Yang, J, Yu, L, Wen, J, et al.. Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9\u00a0mg and 10\u00a0mg in Chinese adults with overweight or obesity: a randomised, placebo-controlled, multiple-ascending-dose phase 1b trial. EClinicalMedicine 2022;54. https:\/\/doi.org\/10.1016\/j.eclinm.2022.101691.","DOI":"10.1016\/j.eclinm.2022.101691"},{"key":"2025121209195693612_j_jbcpp-2024-0193_ref_064","doi-asserted-by":"crossref","unstructured":"Malhotra, A, Grunstein, RR, Fietze, I, Weaver, TE, Redline, S, Azarbarzin, A, et al.. Tirzepatide for the treatment of obstructive sleep apnea and obesity. N Engl J Med 2024;391:1193\u2013205. https:\/\/doi.org\/10.1056\/NEJMoa2404881.","DOI":"10.1056\/NEJMoa2404881"},{"key":"2025121209195693612_j_jbcpp-2024-0193_ref_065","doi-asserted-by":"crossref","unstructured":"Sprung, VS, Kemp, GJ, Wilding, JP, Adams, V, Murphy, K, Burgess, M, et al.. Randomised, cOntrolled Multicentre trial of 26\u00a0weeks subcutaneous liraglutide (a glucagon-like peptide-1 receptor Agonist), with or without contiNuous positive airway pressure (CPAP), in patients with type 2 diabetes mellitus (T2DM) and obstructive sleep. BMJ Open 2020;10:e038856. https:\/\/doi.org\/10.1136\/bmjopen-2020-038856.","DOI":"10.1136\/bmjopen-2020-038856"},{"key":"2025121209195693612_j_jbcpp-2024-0193_ref_031","doi-asserted-by":"crossref","unstructured":"Shah, M, Vella, A. Effects of GLP-1 on appetite and weight. Rev Endocr Metab Disord 2014;15:181. https:\/\/doi.org\/10.1007\/S11154-014-9289-5.","DOI":"10.1007\/s11154-014-9289-5"},{"key":"2025121209195693612_j_jbcpp-2024-0193_ref_032","doi-asserted-by":"crossref","unstructured":"Diz-Chaves, Y, Herrera-P\u00e9rez, S, Gonz\u00e1lez-Mat\u00edas, LC, Lamas, JA, Mallo, F. Glucagon-like peptide-1 (GLP-1) in the integration of neural and endocrine responses to stress. Nutrients 2020;12:1\u201332. https:\/\/doi.org\/10.3390\/NU12113304.","DOI":"10.3390\/nu12113304"},{"key":"2025121209195693612_j_jbcpp-2024-0193_ref_033","doi-asserted-by":"crossref","unstructured":"Cabou, C, Burcelin, R. GLP-1, the gut-brain, and brain-periphery axes. Rev Diabet Stud 2011;8:418. https:\/\/doi.org\/10.1900\/RDS.2011.8.418.","DOI":"10.1900\/RDS.2011.8.418"},{"key":"2025121209195693612_j_jbcpp-2024-0193_ref_034","doi-asserted-by":"crossref","unstructured":"Kabahizi, A, Wallace, B, Lieu, L, Chau, D, Dong, Y, Hwang, ES, et al.. Glucagon\u2010like peptide\u20101 (GLP\u20101) signalling in the brain: from neural circuits and metabolism to therapeutics. Br J Pharmacol 2022;179:600. https:\/\/doi.org\/10.1111\/BPH.15682.","DOI":"10.1111\/bph.15682"},{"key":"2025121209195693612_j_jbcpp-2024-0193_ref_067","doi-asserted-by":"crossref","unstructured":"Tuttle, KR, Lakshmanan, MC, Rayner, B, Busch, RS, Zimmermann, AG, Woodward, DB, et al.. Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial. Lancet Diabetes Endocrinol 2018;6:605\u201317. https:\/\/doi.org\/10.1016\/S2213-8587(18)30104-9.","DOI":"10.1016\/S2213-8587(18)30104-9"},{"key":"2025121209195693612_j_jbcpp-2024-0193_ref_068","doi-asserted-by":"crossref","unstructured":"Bergenstal, RM, Wysham, C, Macconell, L, Malloy, J, Walsh, B, Yan, P, et al.. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet 2010;376:431\u20139. https:\/\/doi.org\/10.1016\/S0140-6736(10)60590-9.","DOI":"10.1016\/S0140-6736(10)60590-9"},{"key":"2025121209195693612_j_jbcpp-2024-0193_ref_069","doi-asserted-by":"crossref","unstructured":"Gu, C, Bernstein, N, Mittal, N, Kurnool, S, Schwartz, H, Loomba, R, et al.. Potential therapeutic targets in obesity, sleep apnea, diabetes, and fatty liver disease. J Clin Med 2024;13. https:\/\/doi.org\/10.3390\/jcm13082231.","DOI":"10.3390\/jcm13082231"},{"key":"2025121209195693612_j_jbcpp-2024-0193_ref_070","doi-asserted-by":"crossref","unstructured":"Peppard, PE, Young, T, Palta, M, Dempsey, J, Skatrud, J. Longitudinal study of moderate weight change and sleep-disordered breathing. JAMA 2000;284:3015\u201321. https:\/\/doi.org\/10.1001\/JAMA.284.23.3015.","DOI":"10.1001\/jama.284.23.3015"},{"key":"2025121209195693612_j_jbcpp-2024-0193_ref_071","doi-asserted-by":"crossref","unstructured":"Chirinos, JA, Gurubhagavatula, I, Teff, K, Rader, DJ, Wadden, TA, Townsend, R, et al.. CPAP, weight loss, or both for obstructive sleep apnea. N Engl J Med 2014;370:2265\u201375. https:\/\/doi.org\/10.1056\/NEJMoa1306187.","DOI":"10.1056\/NEJMoa1306187"}],"container-title":["Journal of Basic and Clinical Physiology and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jbcpp-2024-0193\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jbcpp-2024-0193\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T12:10:44Z","timestamp":1765541444000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jbcpp-2024-0193\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,1]]},"references-count":67,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12,13]]},"published-print":{"date-parts":[[2025,1,31]]}},"alternative-id":["10.1515\/jbcpp-2024-0193"],"URL":"https:\/\/doi.org\/10.1515\/jbcpp-2024-0193","relation":{},"ISSN":["2191-0286"],"issn-type":[{"value":"2191-0286","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,1]]}}}